Alkermes plc (ALKS) Financials
ALKS Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-12-31 | 2.1 billion | 933.5 million |
2023-09-30 | 2.3 billion | 923.6 million |
2023-06-30 | 2.2 billion | 906.7 million |
2023-03-31 | 1.9 billion | 917.2 million |
ALKS Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-12-31 | 90.2 million | 25.8 million |
2023-09-30 | 85.3 million | 23.9 million |
2023-06-30 | 206.0 million | 28.5 million |
2023-03-31 | -28.2 million | 22.6 million |
ALKS Net Income
No data available :(
ALKS Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-12-31 | 813.4 million | - | 81.5 million |
2023-09-30 | 995.6 million | - | 93.6 million |
2023-06-30 | 907.2 million | - | 97.5 million |
2023-03-31 | 692.5 million | 289.6 million | 101.4 million |
ALKS Shares Outstanding
ALKS Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-12-31 | 17.0 million | 73.9 million | 24.3 million | 116.3 million |
2023-09-30 | 14.5 million | 97.1 million | 54.6 million | 114.8 million |
2023-06-30 | 9.7 million | 7000 | 205.3 million | - |
2023-03-31 | 6.9 million | 93.6 million | 56.0 million | 118.5 million |
ALKS Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-12-31 | 377.5 million | 79.1 million |
2023-09-30 | 380.9 million | 61.5 million |
2023-06-30 | 617.4 million | 164.0 million |
2023-03-31 | 287.6 million | 58.2 million |
ALKS
Price: $24.01
52 week price:
Payout Ratio Range:
Earnings Per Share: 3.06 USD
P/E Ratio: 22.03
Exchange: NMS
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 283127
Ebitda: 39.2 millionMarket Capitalization: 4.4 billion